Chronic Myelomonocytic Leukemia

启动 Ⅲ 期临床，意味着新药研发距离上市又近了一大步。10 月（数据范围 10.1-10.22），多款国产创新药进入关键 Ⅲ 期临床，这些新药进展涉及恒瑞、瀚森制药、正大天晴、亚盛医药、宜明昂科、宜联生物等企业，我们从中选择部分重点项目跟大家分享。 恒瑞两款 GLP-1R 激动剂启动 Ⅲ 期临床 用于 2 型糖尿病 10 月 21 日，恒瑞在国内启动一项 HRS9531 用于 2 型糖尿病的 Ⅲ 期临床研究。 截图来源：CDE 官网 HRS9531 是恒瑞研发的一种 GLP-1/GIP 双受体激动剂，目前正在开展用于肥胖、2 型糖尿病、多囊卵巢综合征、射血分数保持的心力衰竭合并肥胖等适应症，其中，用于肥胖和 2 型糖尿病已经进展到 Ⅲ 期临床阶段。 10 月 15 日，恒瑞在国内启动一项诺利糖肽注射液（SHR20004）用于 2 型糖尿病的 Ⅲ 期临床。 截图来源：CDE 官网 诺利糖肽是一种 GLP-1 受体激动剂，给药频率为一天一次皮下注射，目前在研适应症主要为肥胖和 2 型糖尿病，其中，肥胖适应症目前正处于 II 期临床。 宜明昂科「替达派西普」首次启动慢性单核细胞白血病 Ⅲ 期临床 10 月 18 日，宜明昂科在 Clinicaltrial 网站登记一项国内Ⅲ期临床（NCT06647862），旨在评估替达派西普联合阿扎胞苷与安慰剂联合阿扎胞苷治疗初诊慢性单核细胞白血病（CMML1-2）患者的疗效和安全性。 截图来源：Clinicaltrials 替达派西普（IMM01）是宜明昂科自主研发的新一代 CD47 靶向分子。该药具有双重机制，既能够阻断来自肿瘤的「别吃我」信号，也能通过 IgG1 激活患者免疫系统的「吃我」信号。此前该药已在国内启动用于经典型霍奇金淋巴瘤三线治疗的关键 Ⅲ 期临床。 本次启动的是替达派西普首个慢性粒单核细胞白血病 Ⅲ 期临床。今年 ESMO 上口头报告的 II 期研究结果显示，替达派西普联合阿扎胞苷针对初治的慢性粒-单核细胞白血病患者具有良好的疗效和耐受性：治疗≥4 个月的患者，总体缓解率 (ORR) 为 87.5%，完全缓解率 (CR) 为 37.5%; 治疗≥6 个月的患者，ORR 为 84.6%，CR 为 46.2%。 恒瑞 Claudin18.2 ADC 首次启动胃癌 Ⅲ 期临床 10 月 18 日，恒瑞在 Clinicaltrial 网站登记一项国内Ⅲ期临床（NCT06649292），以比较 SHR A1904 与研究者选择的治疗在 Claudin18.2 阳性二线晚期或转移性胃或胃食管交界处腺癌患者中的疗效。 截图来源：Clinicaltrials SHR-A1904 是恒瑞自主研发的 Claudin 18.2 ADC。去年 10 月，德国默克通过和恒瑞达成一项高达 14 亿欧元的合作，获得了 SHR-A1904 和恒瑞另一款产品 HRS-1167（第二代 PARP 抑制剂）在中国大陆以外地区的开发、生产和商业化的独家权利。 今年 ESMO 年会上，恒瑞首次公布了 SHR-A1904 治疗胃或胃食管交界处癌（GC/GEJC）的 I 期研究结果。数据显示：在基线和≥1 次基线后评估的患者中，6.0 mg/kg 剂量组中，ORR 和 DCR 分别为 55.6% (5/9) 和 88.9% (8/9)；8.0 mg/kg 剂量组中，ORR 和 DCR 分别为和 36.7% (11/30) 和 86.7% (26/30)。 亚盛医药 Bcl-2 抑制剂 首次启动 MDS 适应症 Ⅲ 期临床 10 月 15 日，亚盛医药在 Clinicaltrial 网站登记一项全球多中心Ⅲ期临床（NCT06641414，GLORA-4），该研究将在美国和中国内地开展，以评估 Lisaftoclax (APG-2575) 联合阿扎胞苷 (AZA) 治疗新诊断的高风险骨髓增生异常综合征 (HR-MDS) 患者的疗效，对照组为安慰剂联合阿扎胞苷。 截图来源：Clinicaltrials APG-2575 是亚盛自主研发的新型口服 Bcl-2 选择性抑制剂。此前，该药已启动两型关键 Ⅲ 期临床，针对的适应症分别为慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（一线）、急性髓系白血病（一线）。 23 年 ASH 年会上，亚盛曾公布了 APG-2575 单独使用或与阿扎胞苷或高三尖杉酯碱联合使用对 AML、MDS 或其他髓系肿瘤成人患者的安全性、药代动力学 (PK) 和疗效数据。其中，针对 MDS 患者的亚组数据显示，ORR 为 70.0%，CR/CRi 率为 60.0%。 翰森制药 TYK2 抑制剂 启动首个 Ⅲ 期临床 10 月 14 日，翰森制药登记一项国内 Ⅲ 期临床（CTR20243822），以评估 HS-10374 治疗成年中重度斑块状银屑病患者的有效性和安全性。这也是 HS-10374 启动的首个关键性注册 Ⅲ 期临床。 截图来源：CDE 官网 HS-10374 是翰森制药自主研发的一款酪氨酸激酶 2（TYK2）选择性变构抑制剂。在今年 10 月刚举行的第 33 届欧洲皮肤病与性病学会年会（EADV 2024）上，翰森制药口头报告了 HS-10374 银屑病 Ⅱ 期临床研究结果数据： 在 PASI75 应答率方面，HS-10374 6 mg 组为 28.6%（P=0.013），12 mg 组为 72.1%（P<0.001），均显著高于安慰剂组的7.5%，达到主要终点； HS-10374 6 mg 组和 12 mg 组的 sPGA 0/1 应答率（分别为 33.3%、65.1%）也显著高于安慰剂组（10.0%）。 此外，HS-10374 治疗银屑病具有良好的安全性 正大天晴罗伐昔替尼启动 Ⅲ 期临床 用于移植物抗宿主病 10 月 11 日，正大天晴 1 类新药启动一项 Ⅲ 期临床研究，评价罗伐昔替尼对比研究者选择的方案在三线及以后中重度慢性移植物抗宿主病中有效性和安全性。 截图来源：CDE 官网 罗伐昔替尼是一款具有全新化学结构的 JAK/ROCK 抑制剂，今年 7 月 13 日已经在国内首次申报上市，用于治疗中高危骨髓纤维化。 正大天晴在 2023EHA 年会上公布的 Ib/II 期临床研究数据表明，罗伐昔替尼在 cGVHD 患者中，毒性可耐受，对各排异器官部位最佳客观缓解率 86.7%，40% 患者 LSS 评分改善≥7 分，73.3% 患者降低激素使用剂量，有望为 cGVHD 患者带来更多的临床治疗选择。 三生国建启动 IL4R 单抗 Ⅲ 期临床 用于慢性鼻窦炎伴鼻息肉病 10 月 10 日，CDE 官网显示，三生国建登记一项在慢性鼻窦炎伴鼻息肉（CRSwNP）受试者中评估 SSGJ-611 的有效性与安全性的多中心、随机、双盲、安慰剂对照 Ⅲ 期临床研究。 截图来源：CDE 官网 SSGJ-611 是三生国建自主研发的 IL-4Rα拮抗剂。今年 8 月 9 日，三生国建宣布 SSGJ-611 治疗慢性鼻窦炎伴鼻息肉 II 期临床研究达到主要终点。 结果显示，在治疗第 16 周时，两个剂量组双侧鼻内镜下鼻息肉评分（NPS）较基线变化分别为-2.12 和-1.61，周平均鼻塞评分（NCS）较基线变化分别为-1.11 和-1.16。 相较于国外已上市的同靶点药物度普利尤单抗在治疗成人 CRSwNP 受试者的临床研究中（SINUS-24 和 SINUS-52 两个研究），第 24 周 NPS 较基线分别降低-1.89 和-1.71。可以看出，SSGJ-611 治疗 CRSwNP 受试者，在第 16 周的疗效应答，与度普利尤单抗第 24 周的应答相似甚至显示较其有更高的疗效趋势（此非头对头对照研究），提示 SSGJ-611 有显著改善 CRSwNP 疾病的潜力。 宜联生物 B7-H3 ADC  启动鼻咽癌 Ⅲ 期临床 10 月 8 日，宜联生物在 Clinicaltrials 登记一项 YL201 用于鼻咽癌（NPC）三线/末线疗法的 Ⅲ 期临床，这是继小细胞肺癌之后，该新药启动的第二个 Ⅲ 期临床研究。 截图来源：Clinicaltrials YL201 是一种靶向 B7-H3 的 ADC，具有肿瘤微环境可激活连接子和新型拓扑异构酶 I 抑制剂有效载荷。 在今年 ESMO 大会上，宜联生物公布了 YL201 在实体瘤患者中的初步临床结果，其中，NPC 队列共计 70 例可评估疗效的患者，既往全部接受过含铂化疗和 anti-PD-(L)1 治疗，75% 接受过 2 线及以上标准治疗。 YL201 在 NPC 患者中的 ORR 为 48.6%（≥2.0 mg/kg ORR 为 48.6%），mPFS 为 7.2 个月（≥2.0 mg/kg mPFS 为 7.2 个月）。在接受过 2 线及以上标准治疗的患者中，ORR 为 51.0%，mPFS 为 7.0 个月，与 NPC 总体人群相当。 封面来源：站酷海洛 Plus 免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。 编辑：vvy PR 稿对接：微信 insightxb 投稿：微信 insightxb；邮箱 insight@dxy.cn 多样化功能、可溯源数据…… Insight 数据库网页版等你体验 点击阅读原文，立刻解锁！

中国上海和香港，2024年10月5日–致力于研发，生产和销售同类首款及/或同类最优血液及实体肿瘤疗法的商业化阶段领先创新生物制药公司–德琪医药有限公司（简称“德琪医药”，香港交易所股票代码：6996.HK）今日宣布，公司将在计划于2024年11月6日至10日在美国圣休斯顿市举行的2024年癌症免疫治疗学会年会（SITC 2024）上公布三项研究成果。 壁报详情如下: ATG-201（CD19 x CD3 T细胞衔接器） 标题：ATG-201，一款新型“2+1”CD19靶向的T细胞衔接器，用于治疗B细胞恶性肿瘤及B细胞相关的自身免疫疾病 摘要编号：1067 SITC免疫工程研讨会壁报展示 日期：2024年11月7日时间：下午3:10 - 5:00（美国中部标准时间） 第三十九届SITC年会壁报展示 日期：2024年11月8日时间：上午9:00 - 下午7:00（美国中部标准时间） ATG-107（FLT3 x CD3 T细胞衔接器）标题：ATG-107，一款新型“2+1”FLT3靶向、基于CD3的T细胞衔接器，在治疗AML的临床前研究中展现出强效疗效摘要编号：1068SITC免疫工程研讨会壁报展示 日期：2024年11月7日时间：下午3:10 - 5:00（美国中部标准时间） 第三十九届SITC年会壁报展示 日期：2024年11月9日时间：上午9:00 - 下午8:30（美国中部标准时间） ATG-106（CDH6 x CD3 T细胞衔接器）标题：ATG-106，一款新型“2+1”CDH6靶向的T细胞衔接器，展示出强效的T细胞依赖性细胞毒性和体内抗肿瘤活性摘要编号：1069第三十九届SITC年会壁报展示 日期：2024年11月8日时间：上午9:00 - 下午7:00（美国中部标准时间） 关于AnTenGager™ 平台 AnTenGager™平台是德琪医药自主研发的T细胞衔接器（TCE）平台。它可以同时结合疾病相关抗原（DAA）和T细胞表达的CD3的独特的空间表位。通过二价结合DAA，它能有效识别并清除低靶抗原表达水平的细胞。此外，AnTenGager™ TCE只在存在DAA的情况下，条件性地激活T细胞，从而降低了系统性的CD3激活和细胞因子释放综合征（CRS）的风险。这为它在治疗自身免疫性疾病、血液系统恶性肿瘤和实体瘤等领域的应用提供了可能。 公司基于AnTenGager™的产品线丰富。这些TCE旨在协同解决自身免疫性疾病和血液学/肿瘤学领域未被满足的临床需求，并有望成为同类最佳或同类首创的解决方案。目前，我们已有一些处于临床启用阶段的主要项目，当中包括ATG-201，一款用于 B 细胞相关自身免疫性疾病的CD19 x CD3 TCE；ATG-102，一款用于急性髓系白血病和慢性粒单核细胞白血病的LILRB4 x CD3 TCE；ATG-106，一款用于卵巢癌和肾癌的CDH6 x CD3 TCE；ATG-107，一款用于急性髓系白血病的FLT3 x CD3 TCE；和ATG-110，一款用于微卫星稳定（MSS）结直肠癌的LY6G6D x CD3 TCE。 关于德琪医药    德琪医药有限公司（简称“德琪医药”，香港交易所股票代码：6996.HK）是一家以研发为驱动，并已进入商业化阶段的生物制药领先企业，以“医者无疆，创新永续”为愿景，德琪医药专注于血液及实体肿瘤领域的同类首款和同类最优疗法的早期研发、临床研究、药物生产及商业化，致力于通过提供突破性疗法，改善全球患者生活质量。 自2017年以来，德琪医药现已建立起一条拥有9款从临床延展至商业化阶段的肿瘤药物资产研发管线，其中，6款产品具有全球权益，3款产品具有亚太权益。公司已在美国及多个亚太市场获得29个临床批件（IND），并递交了10个新药上市申请（NDA）。目前，希维奥®（塞利尼索片）已获得中国大陆、中国台湾、中国香港、中国澳门、韩国、新加坡、马来西亚、泰国和澳大利亚的新药上市批准。 前瞻性陈述    本文所作出的前瞻性陈述仅与本文作出该陈述当日的事件或资料有关。除法律规定外，于作出前瞻性陈述当日之后，无论是否出现新资料、未来事件或其他情况，我们并无责任更新或公开修改任何前瞻性陈述及预料之外的事件。请细阅本文，并理解我们的实际未来业绩或表现可能与预期有重大差异。本文内有关任何董事或本公司意向的陈述或提述乃于本文刊发日期作出。任何该等意向均可能因未来发展而出现变动。有关这些因素和其他可能导致未来业绩与任何前瞻性声明存在重大差异的因素的进一步讨论，请参阅我们截至2023年12月31日的公司年报中描述的其他风险和不确定性，以及之后向香港证券交易所提交的文件。 Antengene to Present Results from Three Programs at the 2024 SITC Annual Meeting Shanghai and Hong Kong, PRC, October 5, 2024 — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that it will present three programs at the 2024 Society of Immunology in Cancer Annual Meeting (SITC 2024) to be held in Houston from November 6-10, 2024. Details of Poster Presentations: ATG-201 (CD19 x CD3 T-cell Engager) Title: ATG-201, a novel “2+1” CD19-targeted T-cell Engager (TCE) for the treatment of B cell malignancies and B cell related autoimmune diseases Abstract Number: 1067 Poster Abstract Presentation at the SITC Immune Engineering Workshop Date: November 7, 2024 Time: 3:10 PM - 5:00 PM (Central Standard Time) Poster Presentation at the SITC 39th Annual Meeting Date: November 8, 2024 Time: 9:00 AM - 7:00 PM (Central Standard Time) ATG-107 (FLT3 x CD3 T-cell Engager) Title: ATG-107, a novel “2+1” CD3-based T-cell Engager (TCE) targeting FLT3, demonstrates potent preclinical efficacy for the treatment of AML Abstract Number: 1068 Poster Abstract Presentation at the SITC Immune Engineering Workshop Date: November 7, 2024 Time: 3:10 PM - 5:00 PM (Central Standard Time) Poster Presentation at the SITC 39th Annual Meeting Date: November 9, 2024 Time: 9:00 AM - 8:30 PM (Central Standard Time) ATG-106 (CDH6 x CD3 T-cell Engager) Title: ATG-106, a novel “2+1” format CDH6-targeted T-cell Engager (TCE), shows potent T cell dependent cytotoxicity and in vivo anti-tumor efficacy Abstract Number: 1069 Poster Presentation at the SITC 39th Annual Meeting Date: November 8, 2024 Time: 9:00 AM - 7:00 PM (Central Standard Time) About the AnTenGager™ Platform  The AnTenGager™ Platform is a proprietary “2+1” T cell engager (TCE) platform developed by Antengene.  AnTenGager™ TCE simultaneously binds to disease-associated antigens (targets) and a unique conformational epitope on CD3 that expressed on T-cells. The bivalent binding to the targets enables detection and depletion of cells with low expression of the targets. In addition, AnTenGager™ TCE activates T cells in a target-dependent manner so that it demonstrates a lower risk of systemic CD3 activation and cytokine release syndrome (CRS), potentially paving the way for their use in autoimmune diseases, hematological malignancies, and solid tumors. Our extensive and diverse pipeline features promising TCEs that aim to address unmet medical needs in autoimmune diseases and hematology/oncology, with best-in-class/first-in-class potential. A few of our lead programs in the IND-enabling stage include ATG-201, a CD19 x CD3 TCE for B cell related autoimmune diseases; ATG-102, a LILRB4 x CD3 TCE for acute myeloid leukemia (AML) and chronic myelomonocytic leukemia; ATG-106, a CDH6 x CD3 TCE for ovarian cancer and kidney cancer; ATG-107, a FLT3 x CD3 TCE for AML; and ATG-110, a LY6G6D x CD3 TCE for microsatellite stable (MSS) colorectal cancer. About Antengene    Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of “Treating Patients Beyond Borders”. Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 29 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand and Australia. Forward-looking statements    The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2023, and the documents subsequently submitted to the Hong Kong Stock Exchange.

SHANGHAI and HONG KONG, Oct. 4, 2024 /PRNewswire/ -- Antengene Corporation Limited (" Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that it will present three programs at the 2024 Society of Immunology in Cancer Annual Meeting (SITC 2024) to be held in Houston from November 6-10, 2024. Details of Poster Presentations: ATG-201 (CD19 x CD3 T-cell Engager) Title: ATG-201, a novel "2+1" CD19-targeted T-cell Engager (TCE) for the treatment of B cell malignancies and B cell related autoimmune diseases Abstract Number: 1067 Poster Abstract Presentation at the SITC Immune Engineering Workshop Date: November 7, 2024 Time: 3:10 PM - 5:00 PM (Central Standard Time) 5:10 AM – 7:00 AM, Nov 8, 2024 (Beijing Time) Poster Presentation at the SITC 39th Annual Meeting Date: November 8, 2024 Time: 9:00 AM - 7:00 PM (Central Standard Time) 11:00 PM, Nov 8 – 9:00 AM, Nov 9, 2024 (Beijing Time) ATG-107 (FLT3 x CD3 T-cell Engager) Title: ATG-107, a novel "2+1" CD3-based T-cell Engager (TCE) targeting FLT3, demonstrates potent preclinical efficacy for the treatment of AML Abstract Number: 1068 Poster Abstract Presentation at the SITC Immune Engineering Workshop Date: November 7, 2024 Time: 3:10 PM - 5:00 PM (Central Standard Time) 5:10 AM – 7:00 AM, Nov 8, 2024 (Beijing Time) Poster Presentation at the SITC 39th Annual Meeting Date: November 9, 2024 Time: 9:00 AM - 8:30 PM (Central Standard Time) 11:00 PM, Nov 9 – 10:30 AM, Nov 10, 2024 (Beijing Time) ATG-106 (CDH6 x CD3 T-cell Engager) Title: ATG-106, a novel "2+1" format CDH6-targeted T-cell Engager (TCE), shows potent T cell dependent cytotoxicity and in vivo anti-tumor efficacy Abstract Number: 1069 Poster Presentation at the SITC 39th Annual Meeting Date: November 8, 2024 Time: 9:00 AM - 7:00 PM (Central Standard Time) 11:00 PM, Nov 8 – 9:00 AM, Nov 9, 2024 (Beijing Time) About the AnTenGager™ Platform The AnTenGager™ Platform is a proprietary "2+1" T cell engager (TCE) platform developed by Antengene. AnTenGager™ TCE simultaneously binds to disease-associated antigens (targets) and a unique conformational epitope on CD3 that expressed on T-cells. The bivalent binding to the targets enables detection and depletion of cells with low expression of the targets. In addition, AnTenGager™ TCE activates T cells in a target-dependent manner so that it demonstrates a lower risk of systemic CD3 activation and cytokine release syndrome (CRS), potentially paving the way for their use in autoimmune diseases, hematological malignancies, and solid tumors. Our extensive and diverse pipeline features promising TCEs that aim to address unmet medical needs in autoimmune diseases and hematology/oncology, with best-in-class/first-in-class potential. A few of our lead programs in the IND-enabling stage include ATG-201, a CD19 x CD3 TCE for B cell related autoimmune diseases; ATG-102, a LILRB4 x CD3 TCE for acute myeloid leukemia (AML) and chronic myelomonocytic leukemia; ATG-106, a CDH6 x CD3 TCE for ovarian cancer and kidney cancer; ATG-107, a FLT3 x CD3 TCE for AML; and ATG-110, a LY6G6D x CD3 TCE for microsatellite stable (MSS) colorectal cancer. About Antengene Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 29 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2023, and the documents subsequently submitted to the Hong Kong Stock Exchange. SOURCE Antengene Corporation Limited WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED